The grant, stated plainly. On December 29, 2020, Janssen Pharmaceutica was issued US10875902B2, "Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof." The CPC tags — C07K 14/605 (the GLP-1 peptide family), A61K 47/66 (conjugation), plus A61P 3/06 and A61P 3/10 (lipid and diabetes indications) — describe a deliberately combined construct.
Why an event-driven desk notes it: the structural idea here is combination by design — engineering a single molecule to engage GLP-1 and PYY pathways together, rather than co-administering two drugs. That is the kind of mechanism that, if it advances, reframes the competitive set in obesity and metabolic disease.
The disciplined read: a combination-construct grant is an exclusivity claim on a way of fusing two pathways, not on a clinical outcome. The business stakes ride on whether the combined construct does in patients what the design promises — and that is a separate question answered by trial data, not by the patent.
What the grant does not say: nothing about efficacy, safety, or approval. It does not establish superiority over single-pathway agonists, and it does not clear the surrounding peptide IP. Those are distinct facts in distinct records.
The takeaway: when scanning the metabolic pipeline for the next mechanism, read the combination-construct grants for what they actually fuse. Janssen's December 2020 GLP-1/PYY grant is a concrete, dated marker of the combination thesis the field has continued to pursue.